When biotinylated antibodies, such as CD19 and CD20, are injected into patients, the antibodies can bind to the tumor cells and biotin‐bound CAR‐T cells can bind to these biotinylated antibodies on tumor cells to activate T cells [97]. This evidence concerns the gene CD19 and neoplasm.